A New Therapeutic Vaccine Against Prostate Cancer.
A newly approved beneficial prostate cancer vaccine won the guy wire Wednesday of a Medicare consultive committee, increasing the chances that Medicare will pay for the drug. Officials from Medicare, the federal guaranty program for the elderly and disabled, will consider the committee's vote when making a final decision on payment. Such a finding is expected in several months, the Wall Street Journal reported. The vaccine, called Provenge and made by the Dendreon Corp, costs $93000 per determined and extends survival by about four months on average, according to results from clinical trials.
A swotting published in July in the New England Journal of Medicine found that the vaccine extended the lives of men with metastatic tumors rebellious to orthodox hormonal treatment, compared with no treatment. And the therapy involved less toxicity than chemotherapy.
Provenge is a medicinal (not preventive) vaccine made from the patient's own white blood cells. Once removed from the patient, the cells are treated with the anaesthetize and placed back into the patient. These treated cells then trigger an inoculated response that in turn kills cancer cells, leaving usual cells unharmed.
The vaccine is given intravenously in a three-dose schedule delivered in two-week intervals. "The plan of trying to harness the immune system to fight cancer has been something that tribe have tried to attain for many years; this is one such strategy," study lead researcher Dr Philip Kantoff, a professor of medicament at Harvard Medical School and a medical oncologist at the Dana-Farber Cancer Institute in Boston, told HealthDay.
Showing posts with label provenge. Show all posts
Showing posts with label provenge. Show all posts
Friday 16 September 2016
Sunday 17 November 2013
An Approved Vaccine To Treat Prostate Cancer Has Few Side Effects
An Approved Vaccine To Treat Prostate Cancer Has Few Side Effects.
The newly approved health-giving prostate cancer vaccine, Provenge, is tried and true and has few sect effects, a new study finds. In April, the US Food and Drug Administration approved the vaccine for use in men with advanced prostate cancer who had failed hormone therapy. "Provenge was approved based on both aegis and clinical data," said steer researcher Dr Simon J Hall, armchair of urology at Mount Sinai Medical Center in New York City.
This safeness data shows that there are very limited side effects, Hall added. The usefulness of the vaccine for patients with metastatic hormone-resistant prostate cancer is that it has fewer ancillary effects than chemotherapy, which is the only other treatment option for these patients, Hall explained. In addition, Provenge has improved survival over chemotherapy, he added.
The common survival time for men given Provenge is 4,5 months, although some patients adage their lives extended by two to three years. "This is a newly handy treatment, with very limited side effects, compared to anything else that a man would be making allowance for in this state," Hall said. Hall was to present the results on Monday at the American Urological Association annual converging in San Francisco.
Data from four phase 3 trials, which included 904 men randomized to either Provenge or placebo, showed the vaccine extended survival, improved prominence of sentience and had only mild side effects. In fact, more than 83 percent of the men who received Provenge were able to do play activities without any restrictions, the researchers noted.
The newly approved health-giving prostate cancer vaccine, Provenge, is tried and true and has few sect effects, a new study finds. In April, the US Food and Drug Administration approved the vaccine for use in men with advanced prostate cancer who had failed hormone therapy. "Provenge was approved based on both aegis and clinical data," said steer researcher Dr Simon J Hall, armchair of urology at Mount Sinai Medical Center in New York City.
This safeness data shows that there are very limited side effects, Hall added. The usefulness of the vaccine for patients with metastatic hormone-resistant prostate cancer is that it has fewer ancillary effects than chemotherapy, which is the only other treatment option for these patients, Hall explained. In addition, Provenge has improved survival over chemotherapy, he added.
The common survival time for men given Provenge is 4,5 months, although some patients adage their lives extended by two to three years. "This is a newly handy treatment, with very limited side effects, compared to anything else that a man would be making allowance for in this state," Hall said. Hall was to present the results on Monday at the American Urological Association annual converging in San Francisco.
Data from four phase 3 trials, which included 904 men randomized to either Provenge or placebo, showed the vaccine extended survival, improved prominence of sentience and had only mild side effects. In fact, more than 83 percent of the men who received Provenge were able to do play activities without any restrictions, the researchers noted.
Subscribe to:
Posts (Atom)